The company was developed by a team of University at Buffalo neurosurgeons and researchers.
Brought to life by UB neurosurgeons and neuroscientists.
Taught on 1,600 patient cases.
Subject to extensive research, development and testing.
QAS.AI’s team thinks it is finally time to bring their innovative software platform to the market, using AI to help doctors make better decisions during surgery.
But first: the company is raising a $2-3M round that will support the regulatory pathway for “software as a medical device,” a necessary precursor before QAS.AI becomes a standard part of surgical suite sold by companies such as Siemens and Canon Medical Systems.
"We've demonstrated the science and shown that the technology can work in real clinical environments," said Dr. Ciprian Ionita, co-founder and scientific lead of QAS.AI. "The next step is proving through clinical trials that using this information improves patient outcomes."
QAS.AI is now led by CEO Michael Cournyea, who also leads UB Neurosurgery, along with Dr. Jason Davis as chief medical officer and Vincent Tutino as chief financial officer.
The company has received deep support from Buffalo’s life sciences and economic development establishment, including funding from UB’s CAT and Innovation Seed Fund programs. Clinical partners include Kaleida Heath’s Gates Vascular Institute and Catholic Health’s Mercy Hospital of Buffalo.
The QAS.AI platform analyzes imaging data during neurovascular procedures and provides real-time decision support to physicians. The goal is to bring data into the operating room, supporting their experience and instincts.
Davies recently addressed a room full of investors and industry stakeholders during the “Lightning pitch” session at the Medtech Innovator Radar Forum in Manhattan Beach, California.
He said the tool was built by doctors and researchers in Buffalo who know that more information can lead to better outcomes for patients facing critical procedures.
"We wanted to take the things I interpret with my eyes and my gut and turn them into something quantitative," Davies said. "Something we can use to predict treatment outcomes.
Guidesly was among 11 companies recently “drafted” onto the Series B[uffalo] team by Buffalo Bills legend Eric Wood, honoring its momentum and growth projections. This is the second in a series of profiles on those companies.
The others include:
